SK Bioscience Considers Plant Expansion for Pneumococcal Vaccine

---

Researched by Industrial Info Resources (Sugar Land, Texas)--SK Bioscience (Seoul, South Korea) in June announced that its Phase 2 clinical trial of the 21 valence pneumococcal vaccine SKYPAC, which is being developed in collaboration with Sanofi (NASDAQ:SNY) (Paris, France), had successfully ended.

SKYPAC is being developed as a first-in-class 21-valent pneumococcal vaccine for children and infants.

Based on the results of Phase 2 clinical trials, SK Bioscience and Sanofi aim to complete Phase 3 clinical trials in 2027 for infants and toddlers in multiple countries such as the United States, Europe, and South Korea.

SK is considering expansion of its Andong plant to produce the vaccine, which could occur from 2025 through 2027. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical Project Database can click here to learn more.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 trillion (USD).